Expansion on Stromal Cells Preserves the Undifferentiated State of Human Hematopoietic Stem Cells Despite Compromised Reconstitution Ability

Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, California, United States of America.
PLoS ONE (Impact Factor: 3.23). 01/2013; 8(1):e53912. DOI: 10.1371/journal.pone.0053912
Source: PubMed


Lack of HLA-matched hematopoietic stem cells (HSC) limits the number of patients with life-threatening blood disorders that can be treated by HSC transplantation. So far, insufficient understanding of the regulatory mechanisms governing human HSC has precluded the development of effective protocols for culturing HSC for therapeutic use and molecular studies. We defined a culture system using OP9M2 mesenchymal stem cell (MSC) stroma that protects human hematopoietic stem/progenitor cells (HSPC) from differentiation and apoptosis. In addition, it facilitates a dramatic expansion of multipotent progenitors that retain the immunophenotype (CD34+CD38-CD90+) characteristic of human HSPC and proliferative potential over several weeks in culture. In contrast, transplantable HSC could be maintained, but not significantly expanded, during 2-week culture. Temporal analysis of the transcriptome of the ex vivo expanded CD34+CD38-CD90+ cells documented remarkable stability of most transcriptional regulators known to govern the undifferentiated HSC state. Nevertheless, it revealed dynamic fluctuations in transcriptional programs that associate with HSC behavior and may compromise HSC function, such as dysregulation of PBX1 regulated genetic networks. This culture system serves now as a platform for modeling human multilineage hematopoietic stem/progenitor cell hierarchy and studying the complex regulation of HSC identity and function required for successful ex vivo expansion of transplantable HSC.

Download full-text


Available from: Ben Van Handel, Jul 03, 2014
22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leukemic stem cells (LSCs) are considered a major cause of relapse in acute myeloid leukemia (AML). Defining pathways that control LSC self-renewal is crucial for a better understanding of underlying mechanisms and for the development of targeted therapies. However, currently available culture conditions do not prevent spontaneous differentiation of LSCs, which greatly limits the feasibility of cell-based assays. To overcome these constraints we conducted a high-throughput chemical screen and identified small molecules that inhibit differentiation and support LSC activity in vitro. Similar to reports with cord blood stem cells, several of these compounds suppressed the aryl-hydrocarbon receptor (AhR) pathway, which we show to be inactive in vivo and rapidly activated ex vivo in AML cells. We also identified a compound, UM729, that collaborates with AhR suppressors in preventing AML cell differentiation. Together, these findings provide newly defined culture conditions for improved ex vivo culture of primary human AML cells.
    Nature Methods 02/2014; 11(4). DOI:10.1038/nmeth.2847 · 32.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell-based therapies hold a great promise for treatment of a wide array of tragic diseases. Specifically, the use of cellular vehicle platforms emerges as a powerful strategy for targeted delivery of therapeutics to sites of disease. In this chapter, we first review the success and current challenges of different cell therapies, focusing on pancreatic islet transplantation as well as multiple types of stem cell therapies. We then shift our discussion to cellular delivery systems. Efficient cell targeting to desired sites is a crucial aspect towards effective use of such platforms. Accordingly, we thoroughly discuss a variety of cell engineering strategies to improve cell targeting to sites of interest. We then discuss key aspects of cellular delivery, including the types and characteristics of different nanosystems, candidate therapeutic agents and cell types suitable for this approach. Finally, we conclude with a case study of Trojan Horse cell-based cancer therapy.
    Micro- and Nanoengineering of the Cell Surface, Edited by Jeffrey Karp, Weian Zhao, 06/2014: chapter 12: pages 253–279; Elsevier., ISBN: 978-1-4557-3146-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic stem cells (HSCs) sustain blood production through life and are of pivotal importance in regenerative medicine. Although HSC generation from pluripotent stem cells would resolve their shortage for clinical applications, this has not yet been achieved mainly due to the poor mechanistic understanding of their programing. Bone marrow HSCs are first created during embryogenesis in the dorsal aorta (DA) of the mid-gestation conceptus, from where they migrate to the fetal liver and, eventually, the bone marrow. It is currently accepted that HSCs emerge from specialised endothelium, the hemogenic endothelium, localised in the ventral wall of the DA through an evolutionarily conserved process called the endothelial to hematopoietic transition (EHT). However, EHT represents one of the last steps in HSC creation and an understanding of earlier events in the specification of their progenitors is required if we are to create them from naïve pluripotent cells. Due to their ready availability and external development, studies on zebrafish and Xenopus embryos have enormously facilitated our understanding of the early developmental processes leading to the programming of HSCs from nascent lateral plate mesoderm to hemogenic endothelium in the DA. The amenity of the Xenopus model to lineage tracing experiments has also contributed to the establishment of the distinct origins of embryonic (yolk sac) and adult (HSC) hematopoiesis, whilst the transparency of the zebrafish has allowed in vivo imaging of developing blood cells, particularly during and after the emergence of HSCs in the DA. Here, we discuss the key contributions of these model organisms to our understanding of developmental hematopoiesis.
    Experimental Hematology 06/2014; 42(8). DOI:10.1016/j.exphem.2014.06.001 · 2.48 Impact Factor
Show more